TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02310152

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Parent-Based Treatment of Child and Adolescent Anxiety Disorders
Description: Supportive Parenting for Anxious Childhood Emotions

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: CBT
Description: Cognitive Behavioral Therapy
Study: NCT01596972

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: dBest semi-quantitative urine pregnancy test
Description: The dBest® semi-quantitative urine pregnancy test (Figure 2) is a graduated urine pregnancy test with five different levels of sensitivity: 25 IU/L, 100 IU/L, 500 IU/L, 2000 IU/L, 10000 IU/L. The test detects the level of serum hCG that corresponds to the range between that level and the level above it, i.e. the test would be positive at 500 if the hCG was either 501 or 1999. The tool was validated in a US sample of 196 women, where there was a correlation of 69% between urine hCG and serum hCG. Furthermore, the test had a 10% false negative rate (i.e. recording a level two gradations below the serum level) and a 6% false positive rate (i.e. recording a level two gradations above the serum level)
Study: NCT04206982

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Linear ablation in the left and right atria
Description: Ablation of the mitral, the roof, and the cavo-tricuspid isthmus.
Study: NCT01646450

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Icotinib
Description: Icotinib: 125mg, oral administration, three times per day.
Study: NCT00042731

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Lycopene
Description: Daily administration as outlined in treatment arm(s)

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Multivitamin
Description: Daily administration as outlined in treatment arm(s)

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Multivitamin
Description: Daily administration as outlined in treatment arm(s)

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Multivitamin
Description: Daily administration as outlined in treatment arm(s)

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Soy isoflavones
Description: Daily administration as outlined in treatment arm(s)
Study: NCT01153113

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: hTERT mRNA DC
Description: Subjects receive 1x107 cells per infusion administered ID at study week 1, 2, 3, 4, 5, 6 then receive 5x106 cells per infusion administered ID at study weeks 10, 14, 18, 22, 26, 30, 34, 38, 42, 46 and 50.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: hTERT mRNA DC
Description: Subjects receive 1x107 cells per infusion administered ID at study week 1, 2, 3, 4, 5, 6 then receive 1x107 cells per infusion administered ID at study weeks 10, 14, 18, 22, 26, 30, 34, 38, 42, 46 and 50.
Study: NCT04633941

Intervention type: OTHER
Intervention: Standard Care
Description: Standard Care

Intervention type: OTHER
Intervention: Standard Care
Description: Standard Care
Study: NCT00991549

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: interdisciplinary intervention or meeting-seminars
Description: one-year individualized interdisciplinary weight loss program vs. small group seminars on healthy lifestyle

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: interdisciplinary intervention or meeting-seminars
Description: one-year individualized interdisciplinary weight loss program vs. small group seminars on healthy lifestyle
Study: NCT03028389

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: limb remote ischemic preconditioning(LRIP)
Description: LRIP consisted of three cycles of left upper limb ischemia induced by inflating a blood pressure cuff on the left upper arm to 200mmHg, with an intervening 5 minutes of reperfusion, during which time the cuff was deflated.
Study: NCT04480385

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Remote Automated Monitoring System
Description: The patient will be monitored with conventional monitoring devices as well as the MultiSense patch
Study: NCT02084316

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: One4All
Description: Participants with HIV-positive screening results on EIA will immediately have their blood drawn for CD4 and VL tests. Participants will receive post-screening test counseling. Two venous blood samples will be collected-one for immediate numeration of CD4 T-lymphocytes in the same hospital lave using PIMA POC CD4 analyzer and the other for later VL testing at the province CDC which takes 10-15 days. Participant will be notified in person of their CD4 results on the same day and provided post-CD4 test counseling. Counseling in the One4all intervention has been modified from the national SOC guidelines due to the different order of tests and the shortened time period between screening and CD4 testing. The participant will be provided with a tentative assessment of ART eligibility based on CD4 results and other factors. Those who are eligible for ART are encouraged to seek HIV care at the study hospitals via China's National Free ART program.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: The control condition is the current standard of care (SOC) utilized within the county hospitals in Guangxi China. This SOC has some variability between counties but in general follows the national policies. After the initial positive screening on EIA and subsequent repeat screening, participants will receive post-screening test counseling. Participants will then be tested by WB either at the same visit or a subsequent visit. The WB is sent offsite.~After WB test results are reported to the hospital, the health care provider will contact the participant by phone. The participant will be asked to return to the hospital for results and post-WB test counseling. At this visit, a blood sample will be collected for CD4 testing, and an initial epidemiological investigation will be carried out.~Once CD4 test results are available, participants must be located again to inform them of their results and ART eligibility and to provide post-CD4 test counseling.
Study: NCT02074436

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EACA
Description: EACA 1000 mg twice a day. Patients will receive platelet transfusion in case of grade ≥ 2 bleeding.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Platelet transfusion
Description: Prophylactic platelet transfusion. Additional platelet transfusions will be administered in case of grade ≥ 2 bleeding.
Study: NCT03041493

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Electronic cigarette
Description: During the first encounter, blood pressure and endothelium-dependent relaxation (EDR) will be measured by flow mediated dilatation (FMD), and a small peripheral IV catheter will be placed in the participant's median antecubital or cephalic vein. A blood sample (10 mL) for EPCs and F2-isoprostanes will be collected. One urine sample will also be collected for measurement of urinary F2-isoprostanes, cotinine and creatinine. These will serve as both baseline measures for subsequent acute exposure to nicotine and as measures of chronic nicotine exposure. The second encounter will be scheduled 4 hours after the first encounter. At that time a blood sample (5 mL) for EPCs will be collected followed by harvesting of vascular endothelial cells for eNOS and NF-κB expression.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: traditional cigarette
Description: During the first encounter, blood pressure and endothelium-dependent relaxation (EDR) will be measured by flow mediated dilatation (FMD), and a small peripheral IV catheter will be placed in the participant's median antecubital or cephalic vein. A blood sample (10 mL) for EPCs and F2-isoprostanes will be collected. One urine sample will also be collected for measurement of urinary F2-isoprostanes, cotinine and creatinine. These will serve as both baseline measures for subsequent acute exposure to nicotine and as measures of chronic nicotine exposure. The second encounter will be scheduled 4 hours after the first encounter. At that time a blood sample (5 mL) for EPCs will be collected followed by harvesting of vascular endothelial cells for eNOS and NF-κB expression.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: (sham cigarette) - no actual exposure to cigarettes
Description: During the first encounter, blood pressure and endothelium-dependent relaxation (EDR) will be measured by flow mediated dilatation (FMD), and a small peripheral IV catheter will be placed in the participant's median antecubital or cephalic vein. A blood sample (10 mL) for EPCs and F2-isoprostanes will be collected. One urine sample will also be collected for measurement of urinary F2-isoprostanes, cotinine and creatinine. These will be compared to the second set of laboratory measurements done at the second encounter that will be scheduled 4 hours after the first encounter. At that time an additional blood sample (5 mL) for EPCs will be collected followed by harvesting of vascular endothelial cells for eNOS and NF-κB expression.
Study: NCT01860131

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Weight Wise Community Modules
Description: Program designed to educate patients regarding proper diet, exercise,and behavioural modification techniques with emphasis on increasing self-management, enhancing self-efficacy and identifying/overcoming barriers to success.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Weight Wise Community Modules
Description: Program designed to educate patients regarding proper diet, exercise,and behavioural modification techniques with emphasis on increasing self-management, enhancing self-efficacy and identifying/overcoming barriers to success.
Study: NCT00557284

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Montelukast
Description: 4 mg oral granules for ages 12 - 23 months; 4 mg chewable tablet for 2 - 5 years of age; or 5 mg chewable tablet for 6 - 8 years of of age

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral granules or chewable tablet, PO QD (given oral daily)
Study: NCT02932761

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GnRHa
Description: Two doses of GnRHa were administered by subcutaneous injection. The first dose was injected at the time of hysteroscopy examination, and the second dose was administered one day after the VR surgical procedure.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Vaginal repair of CSD
Description: The procedure of vaginal repair of CSD was shown as following. The bladder was dissected away carefully from the uterus toward the abdominal cavity until the peritoneum was reached. The CSD tissue was cut to the normal healthy muscle after the abdominal cavity had been entered, and the lower uterine segments had been completely exposed. A double layer of 1-0 absorbable interrupted sutures was used to close the incisions.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Vaginal repair of CSD
Description: The procedure of vaginal repair of CSD was shown as following. The bladder was dissected away carefully from the uterus toward the abdominal cavity until the peritoneum was reached. The CSD tissue was cut to the normal healthy muscle after the abdominal cavity had been entered, and the lower uterine segments had been completely exposed. A double layer of 1-0 absorbable interrupted sutures was used to close the incisions.
Study: NCT01238705

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Felodipine add Irbesartan
Description: Felodipine Sustained Release Tablets,5mg/day,AstraZeneca Pharmaceutical Co.Ltd., Registration Number: H20030415.~Irbesartan,150mg/day, Sanofi - Aventis Pharmaceutical company, Registration Number: H20080074.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Felodipine add Metoprolol
Description: Felodipine Sustained Release Tablets,5mg/day,AstraZeneca Pharmaceutical Co.Ltd., Registration Number: H20030415.~Metoprolol Succinate,47.5mg/day,AstraZeneca Pharmaceutical Co.Ltd., Registration Number: J20050061.
Study: NCT02176005

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DAV132
Description: DAV132 is associated to moxifloxacin or it is evaluated alone

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DAV132
Description: DAV132 is associated to moxifloxacin or it is evaluated alone

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Moxifloxacin
Description: Moxifloxacin is used alone or associated to DAV132

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxifloxacin
Description: Moxifloxacin is used alone or associated to DAV132

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Negative Control
Description: Moxifloxacin is used alone
Study: NCT00995215

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Spinal Cord Stimulation
Description: The participant will have wire electrodes temporarily placed - by a routine surgical procedure - over the surface of the spinal cord on the lower back. These electrodes will be activated in the operating room and the degree of muscle activation assessed. The wire electrodes will then be removed. Small, disc electrodes will then be permanently implanted to stimulate expiratory muscles and restore cough. These electrodes are activated using an external control unit.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Expiratory Muscle Stimulator
Description: The expiratory muscle stimulator consists of three small electrodes (metal discs) implanted over the surface of their spinal cords on the lower back to stimulate the expiratory muscles and restore cough. These electrodes are connected to an implanted receiver in the abdomen or chest wall. The device is activated through an external antenna connected to an external control box.
Study: NCT01006915

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery
Description: Surgical decompression of the common peroneal, tibial, and deep peroneal nerves
Study: NCT00033293

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Clinical Observation
Description: Undergo observation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Correlative studies
Study: NCT01888783

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tactile acuity measured by 2PD and the GOT
Description: For a detailed description of the methods see outcome measures

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Tactile acuity measured by 2PD and the GOT
Description: For a detailed description of the methods see outcome measures
Study: NCT00033293

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Magnetic Resonance Imaging
Description: Correlative studies
Study: NCT01888783

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Tactile acuity measured by 2PD and the GOT
Description: For a detailed description of the methods see outcome measures
Study: NCT03718806

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zoliflodacin
Description: oral suspension; oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zoliflodacin
Description: oral suspension; oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zoliflodacin
Description: oral suspension; oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zoliflodacin
Description: oral suspension; oral administration

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: high calorie, high fat breakfast
Description: fasted/fed conditions

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: high calorie, high fat breakfast
Description: fasted/fed conditions
Study: NCT03511014

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Microcurrent
Description: Micrucurrent will be apply

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Microcurrent
Description: Micrucurrent will be apply
Study: NCT02904850

Intervention type: BIOLOGICAL
Intervention: group of patients
Description: Plasma dosage of erlotinib and OSI-420 is made from the blood usually taken Further information are collected in the medical record of the patient during the CT scan reassessment after collection.
Study: NCT00033293

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Given orally

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone
Description: Given orally

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Therapeutic Immune Globulin
Description: Given IV
Study: NCT02087241

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD1775
Description: AZD1775 is a highly selective, adenosine-triphosphate (ATP) competitive, small molecule inhibitor of the WEE 1 kinase that sensitizes tumor cells to cytotoxic agents and is being developed for the treatment of advanced solid tumors and p53 pathway deficient malignancies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD1775 Matching Placebo
Description: AZD1775 is a highly selective, adenosine-triphosphate (ATP) competitive, small molecule inhibitor of the WEE 1 kinase that sensitizes tumor cells to cytotoxic agents and is being developed for the treatment of advanced solid tumors and p53 pathway deficient malignancies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pemetrexed
Description: This drug is a part of a general group of chemotherapy drugs called anti-metabolites. It prevents cells from using folate to make DNA and RNA. Because cancer cells need these substances to make new cells, this drug helps to stop the growth of cancer cells.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pemetrexed
Description: This drug is a part of a general group of chemotherapy drugs called anti-metabolites. It prevents cells from using folate to make DNA and RNA. Because cancer cells need these substances to make new cells, this drug helps to stop the growth of cancer cells.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: This drug is a platinum chemotherapy drug that acts like an alkylating agent. It stops the growth of cancer cells, causing the cells to die.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: This drug is a platinum chemotherapy drug that acts like an alkylating agent. It stops the growth of cancer cells, causing the cells to die.
Study: NCT00006463

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ECTEINASCIDIN 743

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ECTEINASCIDIN 743
Study: NCT02935907

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: APG-115
Description: Multiple dose cohorts, PO, every other day of a 28 day cycle
Study: NCT06117072

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: diet plan
Description: One group (n = 30) received the DASH diet and the other group received a salt-free diet (n = 30) and was followed for 2 months
Study: NCT03508973

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sculpta
Study: NCT01830322

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CPI-613
Description: CPI-613 drug product, provided in concentrated form at 50 mg/mL, must be diluted with D5W prior to administration. CPI-613 is to be infused intravenously (IV) via a central venous catheter. CPI-613 will be given 2x weekly, administered on Days 1 and 4 of each of the 3 treatment weeks, followed by a week of rest. The dose of CPI-613 will be 3,000 mg/m2 infused IV over 2 hours (this is approximate maximum tolerated dosing \[MTD\]), via a central venous catheter with D5W running at a rate of about 125-150 mL/hr.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CPI-613
Description: CPI-613 drug product, provided in concentrated form at 50 mg/mL, must be diluted with D5W prior to administration. CPI-613 is to be infused intravenously (IV) via a central venous catheter. CPI-613 will be given 2x weekly, administered on Days 1 and 4 of each of the 3 treatment weeks, followed by a week of rest. The dose of CPI-613 will be 3,000 mg/m2 infused IV over 2 hours (this is approximate maximum tolerated dosing \[MTD\]), via a central venous catheter with D5W running at a rate of about 125-150 mL/hr.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Any non-gemcitabine chemotherapies or best supportive care
Study: NCT02897011

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Methotrexate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Study: NCT02155712

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Triathlon Tritanium Knee
Description: Cementless

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Triathlon Knee
Description: Cemented
Study: NCT01287858

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AC430
Description: Healthy volunteers will either receive AC430 or placebo.
Study: NCT00552851

Intervention type: DRUG
Group type: OTHER
Intervention: pegvisomant
Description: booster dosage 80 mg once sc., than 10 mg once per day, uptitration in steps of 5 mg up to an IGF-1 level in the normal range (every 4 weeks), max. 30 mg once per day. Duration of treatment: one year
Study: NCT02762461

Intervention type: PROCEDURE
Intervention: IVF or ICSI

Intervention type: PROCEDURE
Intervention: IVF or ICSI
Study: NCT01476241

Intervention type: PROCEDURE
Intervention: PEG tube placement
Description: Percutaneous endoscopic gastrostomy
Study: NCT00206323

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Topiramate (drug)
Description: Topiramate 25 mg titrated to 200 mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo/sugar pill
Description: placebo
Study: NCT01964300

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: peginterferon alfa-2b
Description: Given subcutaneously (SC)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT02925988

Intervention type: DEVICE
Group type: OTHER
Intervention: EEG monitoring
Description: Neonates will receive their amplitude-integrated EEG monitoring as soon as the indication for monitoring is established, and conventional EEG electrodes will be applied in parallel.
Study: NCT03067974

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine Hcl 100Mg/Ml Inj
Description: 10mg/kg of Ketamine Hcl 100Mg/Ml Inj to be administered intranasally for pediatric procedural sedation